The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 09, 1990

Filed:

Apr. 22, 1986
Applicant:
Inventors:

Adi F Gazdar, Potomac, MD (US);

Herbert K Oie, Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N / ; C12N / ; C12R / ;
U.S. Cl.
CPC ...
4352402 ; 435948 ; 43524025 ;
Abstract

Using a serum-free defined medium, a human cell line, NCI-H929, was established from a malignant effusion occuring in a patient with IgAk myeloma. The cultured cells have the morphologic, ultrastructural, biochemical, immunologic and cytochemical features of plasma cells. The cells have rearranged alpha and kappa genes and synthesize and secrete very high amounts of IgAk (>80 .mu.g/10.sup.6 cells/24 hr). The cells express surface immunoglobulin (alpha and kappa), the plasma cell antigen PCA-1, the transferrin receptor (T9) and T10, but lack antigens associated with earlier stages of B cell development (HLA-DR, B1, B2, B4, CALLA), as well as other leukocyte-macrophage antigens and Epstein-Barr virus nuclear antigen. While the tumor cells were predominantly near-diploid, the cultured cells are predominantly near-tetraploid with six copies of chromosome 8, four to six of which have an 8q+ abnormality. The cultured cells have a rearrangement of the cellular c-myc proto-oncogene (located at 8q24) and express c-myc RNA.


Find Patent Forward Citations

Loading…